See the original post here:
Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
Related Post
- CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories - February 6th, 2025
- Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 - February 6th, 2025
- Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - February 6th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 6th, 2025
- Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales - February 6th, 2025
- BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - February 6th, 2025
- North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - February 6th, 2025
- GUERBET : 2024 revenue. - February 6th, 2025
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - February 6th, 2025
- Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - February 6th, 2025
- Shareholding declaration Valneva SE - January 2025 - February 6th, 2025
- CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme - February 6th, 2025
- 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - February 6th, 2025
- Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 6th, 2025
- Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - February 6th, 2025
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli - February 6th, 2025
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - February 6th, 2025
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative... - February 6th, 2025
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - February 6th, 2025
- Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - February 4th, 2025
- Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes - February 4th, 2025
- Iantrek Appoints Adam Szaronos as Chief Executive Officer - February 4th, 2025
- Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - February 4th, 2025
- MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC - February 4th, 2025
- IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer... - February 4th, 2025
- Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 4th, 2025
- Allogene Therapeutics Announces Participation in February Investor Conferences - February 4th, 2025
- SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - February 4th, 2025
- Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - February 4th, 2025
- PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI - February 4th, 2025
- Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - February 4th, 2025
- Turnstone Biologics Announces Plans to Explore Strategic Alternatives - February 4th, 2025
- Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - February 4th, 2025
- Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - February 4th, 2025
- FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness - February 4th, 2025
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 4th, 2025
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - February 2nd, 2025
- Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - February 2nd, 2025
- Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - February 2nd, 2025
- 23andMe Launches New Genetic Report on Osteoporosis - February 2nd, 2025
- Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older - February 2nd, 2025
- CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference - February 2nd, 2025
- Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - February 2nd, 2025
- Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - February 2nd, 2025
- Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - February 2nd, 2025
- NewGen Announces Reverse Stock Split - February 2nd, 2025
- Immutep Quarterly Activities Report Q2 FY25 - February 2nd, 2025
- Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - February 2nd, 2025
- Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade - February 2nd, 2025
- Correction: GUERBET : Financial agenda for 2025 - February 2nd, 2025
- Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - February 2nd, 2025
- Bavarian Nordic – Completion of Share Buy-Back Program - February 2nd, 2025
- Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU - February 2nd, 2025
- Annovis Bio, Inc. Announces Proposed Public Offering - February 2nd, 2025
- Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of... - January 31st, 2025
- PacBio Announces Appointment of Chris Smith to Board of Directors - January 31st, 2025
- SPR Announces Presentation of Four Abstracts Featuring the SPRINT® PNS System at NANS 2025 - January 31st, 2025
- Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
- PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
- Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
- Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
- Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
- Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
- Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
- Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
- Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
- Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
- Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
- Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
- BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
- Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
- Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
- Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
- Alumis Strengthens Leadership Team with Key Appointments - January 28th, 2025
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - January 28th, 2025
- 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - January 28th, 2025
Recent Comments